KDM3B and cancer: Large-scale, broad mutation testing of FBXW7 and KDM3B in individuals with cancer will probably be required to establish the full spectrum of associated cancers, because of the rarity of truncating variants and the challenges in interpreting non-synonymous variation in these genes.